A Long-Term Follow-up Study of the Severe Parkinson's Disease Patients Administered the IPS101A Gene Therapy Product.

Safety Evaluation: Incidence of serious adverse events of special interest

Assess severity and frequency serious adverse events of special interest

Time frame: Baseline to 5 years

Safety Evaluation: Incidence of serious adverse events (SAEs) and adverse events (AEs)

Assess severity and frequency of reported adverse events

Time frame: Baseline to 5 years

Safety Evaluation: Number of participants with clinically-relevant changes in physical exams

The results of the physical examination after administration of the clinical trial drug are compared with those before administration to determine whether clinically significant symptoms occur

Time frame: Baseline to 5 years

Safety Evaluation: Number of participants with clinically-relevant changes in laboratory test

The clinical significance of laboratory test results after administration of a clinical trial drug is confirmed by comparing them with those before administration.

Time frame: Baseline to 5 years